Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2025 Management View CEO Sanj K. Patel emphasized that "Kiniksa ...

Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth –– ARCALYST 2025 expected net product ...

Operator: Thank you for standing by, and welcome to the Kiniksa Pharmaceutical Second Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, today ...

Key Takeaways ARCALYST net product revenue for Q2 2024 stood at $103.4 million, a 90% increase year-over-year. The company has seen over 90% payer approval for completed cases, high physician and ...

The ARCALYST commercialization continues to see meaningful growth with Q4 net product revenue of $71.2 million, putting us at $233.2 million for the past year. We're very encouraged with the ...

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) saw its stock rise 11.4% after posting second-quarter results that topped Wall ...

Summary Kiniksa did very well with arcalyst, buying low, selling well. However, its pipeline does not excite investors. KNSA stock, therefore, remains pretty stagnant, on a year-over-year basis.

Arcalyst outperforms in Q3, driven by continued demand growth and inventory benefit In my Q3 2023 earnings preview article to subscribers, I said Arcalyst should deliver $62-64 million in net ...

The significant rise in total revenue was primarily attributed to ARCALYST’s net product revenue, which surged 90% year-over-year and 31% sequentially to $103.4 million.

The adoption of AI technologies is accelerating the growth of the Arcalyst market, offering organizations the tools they need to stay competitive in an increasingly digital world. AI-powered solutions ...